Nuvation Bio Inc. (NUVB) stock
NUVBNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 4/30107% above fair value
$3.90+0.06 (+1.56%)
Close on Nov 17, 2026Market cap $1.37BP/E –Yield –
Nuvation Bio cash
Cash and short-term investments held at the end of each period.
Nuvation Bio's cash was $660.96M at Jun 30, 2026. For fiscal 2025 it was $529.21M, up 5.3% from the year before. The highest annual figure on record is $765.39M in fiscal 2021.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $529.21M | +5.3% |
| FY2024 | Dec 31, 2024 | $502.69M | -17.8% |
| FY2023 | Dec 31, 2023 | $611.21M | -7.5% |
| FY2022 | Dec 31, 2022 | $661.01M | -13.6% |
| FY2021 | Dec 31, 2021 | $765.39M | +254.8% |
| FY2020 | Dec 31, 2020 | $215.75M | +6119.4% |
| FY2019 | Dec 31, 2019 | $3.47M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $660.96M | +8.8% |
| Q1 FY2026 | Mar 31, 2026 | $533.73M | +15.6% |
| Q4 FY2025 | Dec 31, 2025 | $529.21M | +5.3% |
| Q3 FY2025 | Sep 30, 2025 | $549.05M | -0.0% |
| Q2 FY2025 | Jun 30, 2025 | $607.72M | +5.3% |
| Q1 FY2025 | Mar 31, 2025 | $461.68M | -22.7% |
| Q4 FY2024 | Dec 31, 2024 | $502.69M | -17.8% |
| Q3 FY2024 | Sep 30, 2024 | $549.14M | -11.3% |
| Q2 FY2024 | Jun 30, 2024 | $577.17M | -8.5% |
| Q1 FY2024 | Mar 31, 2024 | $596.98M | -7.7% |
| Q4 FY2023 | Dec 31, 2023 | $611.21M | -7.5% |
| Q3 FY2023 | Sep 30, 2023 | $619.34M | -8.1% |
| Q2 FY2023 | Jun 30, 2023 | $630.90M | -10.4% |
| Q1 FY2023 | Mar 31, 2023 | $646.61M | -12.3% |
| Q4 FY2022 | Dec 31, 2022 | $661.01M | -13.6% |
| Q3 FY2022 | Sep 30, 2022 | $673.95M | -14.9% |
| Q2 FY2022 | Jun 30, 2022 | $703.80M | -12.7% |
| Q1 FY2022 | Mar 31, 2022 | $737.70M | -10.6% |
| Q4 FY2021 | Dec 31, 2021 | $765.39M | +254.8% |
| Q3 FY2021 | Sep 30, 2021 | $791.78M | +9414.3% |
| Q2 FY2021 | Jun 30, 2021 | $806.61M | +8533.3% |
| Q1 FY2021 | Mar 31, 2021 | $824.71M | +15289.3% |
| Q4 FY2020 | Dec 31, 2020 | $215.75M | +6119.4% |
| Q3 FY2020 | Sep 30, 2020 | $8.32M | – |
| Q2 FY2020 | Jun 30, 2020 | $9.34M | – |
| Q1 FY2020 | Mar 31, 2020 | $5.36M | – |
| Q4 FY2019 | Dec 31, 2019 | $3.47M | – |
See a number that looks wrong?